These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38557526)

  • 1. Expression of Cyclin D1 in Urothelial Carcinoma of Urinary Bladder and its Association with Tumour Grade.
    Nahar R; Jinnah MSA; Karim SS; Alam MM; Khatun J; Kabir E; Aktar M
    Mymensingh Med J; 2024 Apr; 33(2):461-465. PubMed ID: 38557526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Cyclin D1 and Heterogeneous Nuclear Ribonucleoprotein-K (HnRNP-K) on Urinary Bladder Carcinogenesis.
    Aboushousha T; Hammam O; Helal N; El Dahshan S
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):513-519. PubMed ID: 29480994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of cyclin D1, HER2, and AMACR expressions with histologic grade in bladder urothelial carcinomas.
    Karakaya YA; Oral E
    Indian J Pathol Microbiol; 2021; 64(1):84-90. PubMed ID: 33433414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
    Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
    J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.
    Mai KT; Flood TA; Williams P; Kos Z; Belanger EC
    Virchows Arch; 2013 Oct; 463(4):575-81. PubMed ID: 23913166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma.
    Lee K; Jung ES; Choi YJ; Lee KY; Lee A
    J Korean Med Sci; 2010 Oct; 25(10):1449-55. PubMed ID: 20890425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
    Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM
    Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
    Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
    Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical Expression of Cyclin D1, Cytokeratin 20, and Uroplakin III in Proliferative Urinary Bladder Lesions Induced by o-Nitroanisole in Fischer 344/N Rats.
    Willson CJ; Flake GP; Sills RC; Kissling GE; Cesta MF
    Vet Pathol; 2016 May; 53(3):682-90. PubMed ID: 26319780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group.
    Liukkonen T; Lipponen P; Raitanen M; Kaasinen E; Ala-Opas M; Rajala P; Kosma VM
    Urol Res; 2000 Oct; 28(5):285-92. PubMed ID: 11127704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder.
    Reis LO; Taheri D; Chaux A; Guner G; Mendoza Rodriguez MA; Bivalacqua TJ; Schoenberg MP; Epstein JI; Netto GJ
    Hum Pathol; 2016 Jan; 47(1):20-5. PubMed ID: 26520419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of p53 Expression Intensity in Urothelial Cancers.
    Qamar S; Inam QA; Ashraf S; Khan MS; Khokhar MA; Awan N
    J Coll Physicians Surg Pak; 2017 Apr; 27(4):232-236. PubMed ID: 28492153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
    Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
    Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin D1 protein overexpression is related to tumor differentiation, but not to tumor progression or proliferative activity, in transitional cell carcinoma of the bladder.
    Suwa Y; Takano Y; Iki M; Takeda M; Asakura T; Noguchi S; Masuda M
    J Urol; 1998 Sep; 160(3 Pt 1):897-900. PubMed ID: 9720584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
    Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Requena MJ; Montironi R
    Am J Clin Pathol; 2004 Sep; 122(3):444-52. PubMed ID: 15362377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.
    Liu JY; Qian D; He LR; Li YH; Liao YJ; Mai SJ; Tian XP; Liu YH; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D
    Mol Cancer; 2013 Nov; 12(1):148. PubMed ID: 24268029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High NF-κB and STAT3 activity in human urothelial carcinoma: a pilot study.
    Degoricija M; Situm M; Korać J; Miljković A; Matić K; Paradžik M; Marinović Terzić I; Jerončić A; Tomić S; Terzić J
    World J Urol; 2014 Dec; 32(6):1469-75. PubMed ID: 24448750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
    Pierconti F; Martini M; Fiorentino V; Cenci T; Capodimonti S; Straccia P; Sacco E; Pugliese D; Cindolo L; Larocca LM; Bassi PF
    Urol Oncol; 2021 Feb; 39(2):131.e17-131.e21. PubMed ID: 32773233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.